Proteomics research on antifibrotic mechanism of combination therapy based on isobaric tags for relative and absolute quantitation technique
10.7501/j.issn.0253-2670.2015.01.015
- Author:
Wen CAO
1
Author Information
1. Department of Pharmacology, Guangxi Medical University
- Publication Type:Journal Article
- Keywords:
Combination therapy;
Epigallocatechin gallate;
Genistein;
Isobaric tags for relative and absolute quantitation;
Liver fibrosis;
Proteomic;
Taurine
- From:
Chinese Traditional and Herbal Drugs
2015;46(1):73-79
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the protein basis and molecular mechanism of combination therapy with epigallocatechin gallate (EGCG), taurine, and genistein on CCl4-induced liver fibrosis in rats using isobaric tags for relative and absolute quantitation (iTRAQ). Methods: The SD rats were randomly divided into normal control, model, and combination therapy (taurine 200 mg/kg + EGCG 30 mg/kg + genistein 20 mg/kg) groups. The rats in the model and combination therapy groups were induced by ig administration of 50% CCl4 for 14 weeks, and the rats in the normal control group were given peanut oil. The combination therapy was started at week 9 for 6 weeks. HE staining of liver tissue was performed to evaluate histopathologic changes. The high-abundance proteins in the serum of model and combination therapy groups were depleted by ProteoMiner Protein Enrichment Kit. Proteins differentially expressed in the serum of those two groups were identified with iTRAQ coupled with LC-ESI-MS/MS technology and analyzed with bioinformatics tools. The expression of representative differential protein (Txn1) was validated by ELISA. Results: A total of 359 proteins with the confidence coefficient above 95% were identified, of which 78 were differential expressed proteins, including 51 up-regulated ones and 27 down-regulated ones. The serum level of Txn1 increased significantly in the combination therapy group compared with the model group (P < 0.05). Conclusion: The combination therapy can alleviate the progression of liver fibrosis effectively by affecting multiple biological processes. The regulation of anti-oxidant defense system and coagulation cascade pathway may be the molecular mechanisms of the combination therapy against liver fibrosis.
